PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
1.18
Positive OCF/share while Biotechnology median is negative. Peter Lynch might see a key advantage in a struggling sector.
1.17
Positive FCF/share while Biotechnology median is negative. Peter Lynch might see a strong edge over peers.
0.97%
Positive ratio while Biotechnology median is negative. Peter Lynch might see better capital usage than the sector.
-3.59
Negative ratio while Biotechnology median is 0.80. Seth Klarman might see a severe mismatch of earnings and cash.
62040.00%
OCF-to-sales ratio of 62040.00% while Biotechnology is zero. Walter Schloss might see a modest advantage in actually generating some cash.